{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:37:37Z","timestamp":1792150657502,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12171478"],"award-info":[{"award-number":["12171478"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12331018"],"award-info":[{"award-number":["12331018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull Math Biol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11538-025-01507-0","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:02:42Z","timestamp":1754910162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Modeling Combination Therapies and T Cell Exhaustion Dynamics in the Tumor Under Immune Checkpoint Blockade"],"prefix":"10.1007","volume":"87","author":[{"given":"Xiulan","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"11","key":"1507_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/intimm\/dxac038","volume":"34","author":"S Ando","year":"2022","unstructured":"Ando S, Araki K (2022) CD8 T-Cell Heterogeneity During T-Cell Exhaustion and PD-1-Targeted Immunotherapy. Int Immunol 34(11):571\u2013577","journal-title":"Int Immunol"},{"issue":"5","key":"1507_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"J-C Beltra","year":"2020","unstructured":"Beltra J-C, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR et al (2020) Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity 52(5):825\u2013841","journal-title":"Immunity"},{"issue":"18","key":"1507_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 375(18):1767\u20131778","journal-title":"N Engl J Med"},{"issue":"7930","key":"1507_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","volume":"610","author":"L Codarri Deak","year":"2022","unstructured":"Codarri Deak L, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC et al (2022) PD-1-cis IL-2R Agonism Yields Better Effectors from Stem-like CD8+ T Cells. Nature 610(7930):161\u2013172","journal-title":"Nature"},{"key":"1507_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.715234","volume":"12","author":"JS Dolina","year":"2021","unstructured":"Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S (2021) CD8+ T Cell Exhaustion in Cancer. Front Immunol 12:715234","journal-title":"Front Immunol"},{"issue":"21","key":"1507_CR6","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028","journal-title":"N Engl J Med"},{"issue":"10027","key":"1507_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387(10027):1540\u20131550","journal-title":"The Lancet"},{"issue":"9","key":"1507_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.mad.2004.07.001","volume":"125","author":"MS Hong","year":"2004","unstructured":"Hong MS, Dan JM, Choi J-Y, Kang I (2004) Age-Associated Changes in the Frequency of Naive, Memory and Effector CD8+ T Cells. Mech Ageing Dev 125(9):615\u2013618","journal-title":"Mech Ageing Dev"},{"issue":"6","key":"1507_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","volume":"51","author":"WH Hudson","year":"2019","unstructured":"Hudson WH, Gensheimer J, Hashimoto M, Wieland A, Valanparambil RM et al (2019) Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells During Chronic Infection. Immunity 51(6):1043\u20131058","journal-title":"Immunity"},{"issue":"7620","key":"1507_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q et al (2016) Defining CD8+ T Cells That Provide the Proliferative Burst After PD-1 Therapy. Nature 537(7620):417\u2013421","journal-title":"Nature"},{"key":"1507_CR11","doi-asserted-by":"crossref","unstructured":"Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., et al. (2016) Defining CD8+ T Cells That Provide the Proliferative Burst After PD-1 Therapy. Nature, 537(7620), 417\u2013421","DOI":"10.1038\/nature19330"},{"issue":"3","key":"1507_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s11538-009-9463-1","volume":"72","author":"PS Kim","year":"2010","unstructured":"Kim PS, Lee PP, Levy D (2010) Emergent Group Dynamics Governed by Regulatory Cells Produce a Robust Primary T Cell Response. Bull Math Biol 72(3):611\u2013644","journal-title":"Bull Math Biol"},{"issue":"1","key":"1507_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","volume":"50","author":"S Kurtulus","year":"2019","unstructured":"Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J et al (2019) Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-$$1^-$$CD$$8^+$$ Tumor-Infiltrating T Cells. Immunity 50(1):181\u2013194","journal-title":"Immunity"},{"issue":"5","key":"1507_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178479","volume":"12","author":"X Lai","year":"2017","unstructured":"Lai X, Friedman A (2017) Combination Therapy of Cancer with Cancer Vaccine and Immune Checkpoint Inhibitors: A Mathematical Model. PLoS ONE 12(5):e0178479","journal-title":"PLoS ONE"},{"key":"1507_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11425-019-1648-6","volume":"63","author":"X Lai","year":"2020","unstructured":"Lai X, Friedman A (2020) Mathematical Modeling of Cancer Treatment with Radiation and PD-L1 Inhibitor. Sci China Math 63:465\u2013484","journal-title":"Sci China Math"},{"key":"1507_CR16","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","volume":"9","author":"Y Liang","year":"2018","unstructured":"Liang Y, Tang H, Guo J, Qiu X, Yang Z, Ren Z et al (2018) Targeting IFN$$\\alpha $$ to Tumor by Anti-PD-L1 Creates Feedforward Antitumor Responses to Overcome Checkpoint Blockade Resistance. Nat Commun 9:4586","journal-title":"Nat Commun"},{"issue":"1","key":"1507_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","volume":"254","author":"S Marino","year":"2008","unstructured":"Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) A Methodology for Performing Global Uncertainty and Sensitivity Analysis in Systems Biology. J Theor Biol 254(1):178\u2013196","journal-title":"J Theor Biol"},{"key":"1507_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ (2019) CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol 37:457\u2013495","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"1507_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV et al (2019) Subsets of Exhausted CD8+ T Cells Differentially Mediate Tumor Control and Respond to Checkpoint Blockade. Nat Immunol 20(3):326\u2013336","journal-title":"Nat Immunol"},{"issue":"7","key":"1507_CR20","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2010.06.019","volume":"141","author":"U Moran","year":"2010","unstructured":"Moran U, Phillips R, Milo R (2010) SnapShot: Key Numbers in Biology. Cell 141(7):1262","journal-title":"Cell"},{"issue":"1","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"S137","DOI":"10.30707\/LiB5.2Nikolopoulou","volume":"5","author":"E Nikolopoulou","year":"2018","unstructured":"Nikolopoulou E, Johnson LR, Harris DC, Nagy JD, Stites EC, Kuang Y (2018) Tumour-Immune Dynamics With an Immune Checkpoint Inhibitor. Lett Biomath 5(1):S137\u2013S159","journal-title":"Lett Biomath"},{"issue":"4","key":"1507_CR22","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.3934\/dcdsb.2020138","volume":"26","author":"E Nikolopoulou","year":"2021","unstructured":"Nikolopoulou E, Eikenberry SE, Gevertz JL, Kuang Y (2021) Mathematical Modeling of an Immune Checkpoint Inhibitor and Its Synergy with an Immunostimulant. Discrete Contin Dyn Syst B 26(4):2133\u20132159","journal-title":"Discrete Contin Dyn Syst B"},{"issue":"6316","key":"1507_CR23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J et al (2016) Epigenetic Stability of Exhausted T Cells Limits Durability of Reinvigoration by PD-1 Blockade. Science 354(6316):1160\u20131165","journal-title":"Science"},{"issue":"4","key":"1507_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip M, Schietinger A (2022) CD8+ T Cell Differentiation and Dysfunction in Cancer. Nat Rev Immunol 22(4):209\u2013223","journal-title":"Nat Rev Immunol"},{"key":"1507_CR25","first-page":"1024","volume":"46","author":"M Philip","year":"2017","unstructured":"Philip M, Fairchild L, Sun L et al (2017) Chromatin States Define Tumor-Specific T Cell Dysfunction and Reprogramming. Immunity 46:1024\u20131038","journal-title":"Immunity"},{"key":"1507_CR26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Cancer Discov 8:1069\u20131086","journal-title":"Cancer Discov"},{"issue":"4","key":"1507_CR27","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M et al (2018) Defining TCF1+ Precursor Exhausted T Cells that Prime Responsiveness to PD-1 Checkpoint Blockade. Cell 175(4):998-1013.e20","journal-title":"Cell"},{"key":"1507_CR28","first-page":"aaf1340","volume":"352","author":"A Schietinger","year":"2016","unstructured":"Schietinger A et al (2016) Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Science 352:aaf1340","journal-title":"Science"},{"issue":"6024","key":"1507_CR29","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion. Science 331(6024):1565\u20131570","journal-title":"Science"},{"key":"1507_CR30","first-page":"72","volume":"543","author":"DR Sen","year":"2016","unstructured":"Sen DR et al (2016) The epigenetic landscape of T cell exhaustion. Nature 543:72\u201377","journal-title":"Nature"},{"key":"1507_CR31","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348:56\u201361","journal-title":"Science"},{"key":"1507_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168:707\u2013723","journal-title":"Cell"},{"issue":"1","key":"1507_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S et al (2019) Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50(1):195\u2013211","journal-title":"Immunity"},{"key":"1507_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11538-023-01207-7","volume":"85","author":"T Simmons","year":"2023","unstructured":"Simmons T, Levy D (2023) Modeling the Development of Cellular Exhaustion and Tumor-Immune Stalemate. Bull Math Biol 85:106","journal-title":"Bull Math Biol"},{"issue":"1","key":"1507_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B (2023) T Cells in Health and Disease. Signal Transduct Target Ther 8(1):235","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1507_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN (2018) T Cell Dysfunction in Cancer. Cancer Cell 33(4):547\u2013562","journal-title":"Cancer Cell"},{"issue":"1","key":"1507_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","volume":"56","author":"M Tichet","year":"2023","unstructured":"Tichet M, Wullschleger S, Chryplewicz A, Fournier N, Marcone R et al (2023) Bispecific PD1-IL2v and Anti-PD-L1 Break Tumor Immunity Resistance by Enhancing Stem-like Tumor-Reactive CD8+ T Cells and Reprogramming Macrophages. Immunity 56(1):162\u2013179","journal-title":"Immunity"},{"issue":"4","key":"1507_CR38","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","volume":"20","author":"AM Van der Leun","year":"2020","unstructured":"Van der Leun AM, Thommen DS, Schumacher TN (2020) CD8+ T Cell States in Human Cancer: Insights from Single-Cell Analysis. Nat Rev Cancer 20(4):218\u2013232","journal-title":"Nat Rev Cancer"},{"issue":"7876","key":"1507_CR39","first-page":"530","volume":"597","author":"X Wu","year":"2021","unstructured":"Wu X, Wu P, Shen Y, Dong L, He X, Wang Y, He Y, Wei L, Chen X, Li Y et al (2021) CXCR5+ Precursor T Cells as Reservoirs for Reinvigoration and Spatial Positioning in Anti-PD-L1 Therapy. Nature 597(7876):530\u2013535","journal-title":"Nature"},{"issue":"4","key":"1507_CR40","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.3934\/mbe.2022190","volume":"19","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Shen J, Zou X (2022) Mathematical Modeling and Dynamical Analysis of Anti-Tumor Drug Dose-Response. Math Biosci Eng 19(4):4120\u20134144","journal-title":"Math Biosci Eng"},{"key":"1507_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2023.111489","volume":"568","author":"L Xue","year":"2023","unstructured":"Xue L, Zhang H, Zheng X, Sun W, Lei J (2023) Treatment of Melanoma with Dendritic Cell Vaccines and Immune Checkpoint Inhibitors: A Mathematical Modeling Study. J Theor Biol 568:111489","journal-title":"J Theor Biol"},{"issue":"6427","key":"1507_CR42","first-page":"641","volume":"363","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA et al (2019) Clonal Replacement of Tumor-Specific T Cells Following PD-1 Blockade. Science 363(6427):641\u2013646","journal-title":"Science"},{"issue":"12","key":"1507_CR43","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.tibs.2018.09.004","volume":"43","author":"J Zhang","year":"2019","unstructured":"Zhang J, Dang F, Ren J, Wei W (2019) Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends Biochem Sci 43(12):1014\u20131032","journal-title":"Trends Biochem Sci"}],"container-title":["Bulletin of Mathematical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-025-01507-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11538-025-01507-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11538-025-01507-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:14:29Z","timestamp":1756898069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11538-025-01507-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s11538-025-01507-0","relation":{},"ISSN":["0092-8240","1522-9602"],"issn-type":[{"value":"0092-8240","type":"print"},{"value":"1522-9602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"128"}}